


Lifeward Ltd. (LFWD)

Nasdaq; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001607962

[illegible]

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

On August 11, 2023, we completed the acquisition of AlterG which became an indirect and wholly-owned subsidiary of the Company. The anticipated benefits from our acquisition of AlterG are based on projections and assumptions about the combined businesses of ReWalk and AlterG, which may not materialize as expected or which may prove to be inaccurate. The value of our ordinary shares could be adversely affected if we are unable to realize the anticipated benefits from the acquisition on a timely basis or at all.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 58.0						
Gross profitability		36.8%	32.2%	36.9	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(11.6%)	(6.6%)	37.0	811	2025-12-31
Gross margin stability, five years		190.3 pts	2.8 pts	100.0	243	2025-12-31
Solvency, sleeve percentile 85.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(44.62)	(0.31)	87.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.31x	2.96x	83.8	839	2025-12-31
Growth and financing, sleeve percentile 61.5						
Revenue growth, three-year compound		58.4%	10.0%	10.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(32.4%)	2.1%	93.6	704	2025-12-31
Net share issuance, one year		72.5%	2.5%	80.1	634	2026-03-17


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 72.5%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
329	Maravai Lifesciences Holdings, Inc. (MRVI)	88.6	E	late filer
330	Insight Molecular Diagnostics Inc. (IMDX)	88.9	E	fortress
331	Nuwellis, Inc. (NUWE)	89.2	E	balance sheet dilution, short runway, fortress
332	Aclaris Therapeutics, Inc. (ACRS)	89.5	E	balance sheet short runway, fortress
333	Brookdale Senior Living Inc. (BKD)	89.7	E	balance sheet
334	Lifeward Ltd. (LFWD) <	90.0	E	dilution, late filer
335	Canopy Growth Corp. (CGC)	90.3	E	dilution, fortress
336	Aytu Biopharma, Inc. (AYTU)	90.5	E	balance sheet fortress
337	Q32 Bio Inc. (QTTB)	90.8	E	balance sheet
338	Editas Medicine, Inc. (EDIT)	91.1	E	fortress
339	Dyadic International Inc. (DYAI)	91.4	E	balance sheet short runway, distress

What the price implies

at the 2026-09-04 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.4%)	8.0%	39
Distance from 52-week high	(35.3%)	(31.4%)	43
EBIT to enterprise value	(214.9%)	(1.5%)	4
Free cash flow yield	(92.5%)	(1.0%)	5
Book value to price	0.67	0.28	76
Sales to price	0.08	0.31	22
Composite equity issuance, five years	196.2%	20.3%	89
Relative strength against the sector, log excess return	(0.32)	(0.14)	39

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$9.4M
Operating cash flow, four quarters	-\$17.1M
Months of runway	6.6
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$39,417

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$8.4M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
2	assets	us-gaap:Assets	\$22.9M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
3	net income	us-gaap:NetIncomeLoss	-\$19.9M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$16.8M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
5	assets	us-gaap:Assets	\$30.5M	2024-12-31	2026-03-18	10-K	0001178913-26-001208
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.4M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
7	gross profit	us-gaap:GrossProfit	\$8.2M	2024-12-31	2026-03-18	10-K	0001178913-26-001208
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.7M	2024-12-31	2025-03-07	10-K	0001178913-25-000736
9	gross profit	us-gaap:GrossProfit	\$4.5M	2023-12-31	2026-03-18	10-K	0001178913-26-001208
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$435,000	2023-12-31	2024-02-27	10-K	0001178913-24-000730
11	gross profit	us-gaap:GrossProfit	\$1.9M	2022-12-31	2025-03-07	10-K	0001178913-25-000736
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$352,000	2022-12-31	2023-02-23	10-K	0001178913-23-000722
13	gross profit	us-gaap:GrossProfit	\$2.9M	2021-12-31	2024-02-27	10-K	0001178913-24-000730
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$432,000	2021-12-31	2022-02-24	10-K	0001178913-22-000800
15	current assets	us-gaap:AssetsCurrent	\$15.8M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
16	current liabilities	us-gaap:LiabilitiesCurrent	\$12.0M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$284.7M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
18	operating income	us-gaap:OperatingIncomeLoss	-\$19.7M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
19	book equity	us-gaap:StockholdersEquity	\$8.4M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
20	liabilities	us-gaap:Liabilities	\$14.5M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$16,000	2025-12-31	2026-03-18	10-K	0001178913-26-001208
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$21.7M	2024-12-31	2026-03-18	10-K	0001178913-26-001208
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2024-12-31	2026-03-18	10-K	0001178913-26-001208
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$20.7M	2023-12-31	2026-03-18	10-K	0001178913-26-001208
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$81,000	2023-12-31	2026-03-18	10-K	0001178913-26-001208
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$17.9M	2022-12-31	2025-03-07	10-K	0001178913-25-000736
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$25,000	2022-12-31	2025-03-07	10-K	0001178913-25-000736
28	depreciation amortization	us-gaap:Depreciation	\$333,000	2025-12-31	2026-03-18	10-K	0001178913-26-001208
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$10.0M	2025-12-31	2026-03-18	10-K	0001178913-26-001208
30	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$55,000	2025-12-31	2026-03-18	10-K	0001178913-26-001208
31	current assets	us-gaap:AssetsCurrent	\$21.3M	2024-12-31	2026-03-18	10-K	0001178913-26-001208
32	current liabilities	us-gaap:LiabilitiesCurrent	\$10.2M	2024-12-31	2026-03-18	10-K	0001178913-26-001208
33	assets	us-gaap:Assets	\$63.2M	2023-12-31	2025-03-07	10-K	0001178913-25-000736
34	assets	us-gaap:Assets	\$74.2M	2022-12-31	2024-02-27	10-K	0001178913-24-000730
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,528,222	2026-03-17	2026-03-18	10-K	0001178913-26-001208
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,630,281	2025-03-06	2025-03-07	10-K	0001178913-25-000736